ArticleInternational journal of clinical and experimental pathology2018
Clinical significance of long non-coding RNA ZEB2-AS1 in locally advanced colorectal cancer.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate the clinical significance of differential expression of long non-coding RNA (lncRNA) ZEB2-AS1 in patients with colorectal cancer (CRC).
methodsmRNA expression of lncRNA ZEB2-AS1 was evaluated by real-time quantitative PCR on eighty-seven cancerous tissues and adjacent normal mucosal tissues from patients with CRC tissue. Correlation between the lncRNA ZEB2-AS1 expression and clinicopathological characteristics of the colorectal cancer patients was evaluated, and five-year overall survival (OS) was also analyzed according to the lncRNA ZEB2-AS1 expression of the CRC patients. Moreover, Cox Regression Analysis was performed in screening prognosis factors.
resultsA significantly upregulated lncRNA ZEB2-AS1 expression, with a fold change of 18.75, was found in CRC tissue compared to the normal tissue. lncRNA ZEB2-AS1 expression in CRC was correlated with death (
conclusionExpression of lncRNA ZEB2-AS1 was significantly upregulated in stage III CRC patients and affects the prognosis.
Indexed as
Identifiers
31938180PMC6957990W3026303853What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.